SLU-PP-332: Novel Insights into ERR Agonist and Exercise Mimetic

Research brief

SLU-PP-332, a potent ERR pan-agonist, mimics exercise-induced physiological responses, showing promise in treating metabolic syndrome and improving exercise performance [Okda et al., 2026; Billon et al., 2024]. Its mechanism enhances mitochondrial function and fatty acid oxidation [de Souza-Lima et al., 2026].

Key findings

• SLU-PP-332 acts as a pan-ERR agonist with strong effect on ERR alpha [Okda et al., 2026]. • It effectively mimics exercise benefits, improving oxidative phosphorylation and mitochondrial function [Billon et al., 2023]. • In metabolic syndrome mouse models, it improves glycemic control and reduces obesity [Billon et al., 2024]. • SLU-PP-332 enhances aerobic performance, though lacks oral bioavailability unlike SLU-PP-915 [Billon et al., 2026]. • It holds therapeutic potential for metabolic disorders and muscular pathologies [Billon et al., 2026].

Detailed research context

Introduction to SLU-PP-332

SLU-PP-332 is a synthetic agonist targeting estrogen-related receptors (ERRs), which play crucial roles in mitochondrial metabolism and transcriptional modulation in response to exercise. ERRs are pivotal in skeletal muscle adaptation [de Souza-Lima et al., 2026]. Despite the challenges in developing compounds effective on the ERR alpha subtype, SLU-PP-332 was specifically designed to address this gap [Billon et al., 2023].

Mechanism of Action

SLU-PP-332's action as a pan-ERR agonist allows it to mimic acute aerobic exercise by activating gene expression programs dependent on ERR alpha, such as Ddit4 and Slc25a25, thereby enhancing mitochondrial function and fatty acid oxidation [Okda et al., 2026; de Souza-Lima et al., 2026]. It supports the development of type IIa oxidative-glycolytic muscle fibers, critical for endurance performance [Billon et al., 2026].

Therapeutic Applications

In preclinical studies, SLU-PP-332 demonstrated efficacy in improving parameters associated with metabolic syndrome. Mice treated with this compound showed increased energy expenditure, reduced adiposity, and enhanced insulin sensitivity [Billon et al., 2024]. These findings suggest a potential role for SLU-PP-332 in treating obesity and related metabolic disorders.

Limitations and Future Directions

While SLU-PP-332 significantly enhances exercise capacity, a limitation is its lack of oral bioavailability contrary to SLU-PP-915, which shares similar agonistic properties but can be administered orally [Billon et al., 2026]. Further clinical trials are necessary to explore the safety and efficacy of SLU-PP-332 in humans [de Souza-Lima et al., 2026]. Understanding its long-term effects and therapeutic range will be crucial steps forward.

Conclusion

SLU-PP-332 stands out as a compelling exercise mimetic with the potential to manage metabolic disorders and improve muscle function, thanks to its deep engagement with ERR pathways. Continued research could pave the way for strategic therapeutic applications, transforming how metabolic and muscle-related diseases are treated [Billon et al., 2026].

Overall, SLU-PP-332 represents a significant advancement in therapeutic exercise mimetics, holding promise for broader medical applications should future studies validate its current preclinical success.

Source method

This research briefing is based on the verified PubMed records linked in the References & Citations section below.